This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Astellas Pharma Gmbh, National Cancer Center. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 425 
3 out of 264 
Years Active: 2024-2025
Title: Masatoshi Yuri: Innovator in Cancer Treatment
Introduction
Masatoshi Yuri is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of bispecific antibodies. With a total of 3 patents, his work focuses on creating targeted therapies that can improve patient outcomes.
Latest Patents
Masatoshi Yuri's latest patents include the development of an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody. The objective of this invention is to provide effective treatments for human patients. A human monoclonal antibody-producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient. This process led to the creation of antibodies 16B11 and 16B12, which selectively bind to peritoneal disseminated cancer cells. These antibodies target the region from amino acid positions 126 to 155 of TSPAN8 and demonstrate strong binding activity to TSPAN8 expressed in these cancer cells. Furthermore, the anti-TSPAN8(16B11)-anti-CD3 bispecific antibody exhibited cytotoxic activity against TSPAN8-expressing cancer cells in vitro and showed anti-tumor action in vivo, extending the lifetime of model mice with peritoneal dissemination.
Another significant patent is the anti-CLDN4/anti-CD137 bispecific antibody. This invention aims to provide a treatment for cancer by utilizing an anti-CLDN4 antibody that binds to CLDN4 and an anti-CD137 antibody that binds to CD137. This bispecific antibody has shown agonistic activity for CD137, promoting interferon γ production by T cells and exhibiting cytotoxic activity against cancer cells expressing CLDN4. Importantly, it has been demonstrated that this antibody can be safely administered to monkeys, indicating its potential for human cancer treatment.
Career Highlights
Masatoshi Yuri has worked with notable organizations such as Astellas Pharma GmbH and the National Cancer Center. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.
Collaborations
Some of his coworkers include Yoshiyuki Tenda and Hiroki Sasaki. Their collaboration has likely played a role in the success of his research endeavors.
Conclusion
Masatoshi Yuri is a key figure in the field of cancer treatment,
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile